Steven Gillis

Seven purchases and two sales of a few thousand euros: the purchases by Steven Gillis make up 78% of the market trades, and they carry the amounts. Five of them, with a stated amount, total EUR 13.7 million, with a median of EUR 3,010,985. The three largest are from September 19, 2019 (EUR 4,525,500 at VBI Vaccines Inc.), May 23, 2016 (EUR 4,457,900 at Phaserx, Inc.) and October 16, 2020 (EUR 3,010,985 at Codiak BioSciences, Inc.). The two sales, of EUR 4,323 and EUR 1,740, date from May 23, 2016, the day of the Phaserx, Inc. purchase.

The 18 filings cover trades dated from May 23, 2016 to July 1, 2026, under the title Director at five companies: VBI Vaccines Inc/BC (6 filings), Codiak BioSciences, Inc. (5), Phaserx, Inc. (3), Takeda Pharmaceutical Co Ltd (1) and VBI Vaccines Inc., listed in Toronto (1). On top come 5 option exercises, one share grant and 3 filings of another kind.

The calendar is discontinuous: 3 filings a year from 2016 to 2018, 2 in 2019, 3 in 2020, then 1 in 2022, 2 in 2023 and 1 in 2026, the only one in the last twelve months. The median publication delay is 4 days.

Gillis' own market trades within 30 days of colleagues number 3, 3 and 2, every one in the same direction. Names in order: Brian G. Atwood (Phaserx, Inc.), Richard J. Ulevitch (Phaserx, Inc.) and ARCH Venture Fund VIII, L.P. (Codiak BioSciences, Inc.).